Treatment-Resistant Depression in Adolescents: A Comprehensive Review

Carlo Carandang*
Assistant Professor, Department of Psychiatry, Dalhousie University, Canada

Abstract

Treatment nonresponse in adolescent depression is a major public health problem, as untreated depression is associated with significant mortality by suicide, protracted course of illness, and recurrence into adulthood. Even with the gold-standard treatment with a Selective Serotonin Reuptake Inhibitor (SSRI) and concurrent Cognitive Behavioral Therapy (CBT), 30% to 40% will not respond to treatment, thus classified as “treatment-resistant”. These depressed adolescent patients who are refractory to first-line treatments are often in such mental anguish that they are not functioning, and some have considered their only option left to end the misery is to suicide. These are the patients who are often referred to psychiatry, but the treatment options for adolescents with treatment-resistant depression are limited due to lack of research in this area. This review will consider the various treatment options that may help to alleviate the suffering of adolescents afflicted with this devastating illness, with the caveat that there are few controlled studies focused on refractory depression in adolescents.

Keywords: Depression; Treatment-resistant; Adolescent; Youth; Review

Major Depression in Youth

Major depressive disorder in youth is associated with significant mortality by suicide [1], protracted course of illness [2], high risk of recurrence [3], significant nonresponse to treatment [4,5], progression to bipolar disorder within 5 years [6-8], and high frequency of affective illness in family members [9]. Even with the gold standard treatment with an SSRI and concurrent cognitive behavioral therapy, 30% to 40% will not respond to treatment, thus classified as “treatment-resistant” [5,10,11]. A meta-analysis of published, randomized, placebo-controlled trials of SSRIs in depressed youth revealed an effect size of only 0.26 [12]. This further illustrates the poor response of SSRIs in youth depression. Treatment-resistant depression is associated with poor prognosis and high risk for suicide, indicating the need for more aggressive and clinically effective treatment than SSRIs alone can provide.

Course of Illness

The challenges of treating depressed youth throughout the course of the illness are illustrated by the following data. The mean duration of a depressive episode in youth is 32 weeks (SD=28weeks), with age of onset having an inverse relationship to time to recovery [2]. In 10% of depressed adolescents, the depressive episode lasted more than 2 years [7]. Within 5 years of the initial diagnosis, 72% of depressed youth developed recurrence [5]. The poor course of illness combined with the poor response of SSRIs in youth depression suggests that a significant number of depressed youth will not respond to first-line treatment with SSRIs.

Is Depression the Right Diagnosis?

Before considering treatment-resistant depression, the clinician should determine if major depressive disorder is the right diagnosis. Obviously, if the diagnosis of depression is incorrect, then treatments for depression will not be effective. Because several disorders can present with similar symptoms, it is important to clarify which disorder best accounts for the symptoms. The differential diagnosis for depression is extensive, and includes: bipolar depression, adjustment disorder with depressed mood, bereavement, post-traumatic stress disorder, Oppositional Defiant Disorder (ODD), Attention-Deficit Hyperactivity Disorder (ADHD), pervasive developmental disorder, and mood disorder due to a general medical condition (including substance-induced depression). Detailed information on the clinical assessment of children and adolescents with depression can be found elsewhere [13].

Other Factors Associated with Poor Treatment Response

Other than the correct diagnosis of depression, clinicians should explore other factors which contribute to poor treatment response. Exploring other factors leading to treatment-resistant depression will also guide why a patient is not responding. Depressed adolescent patients with a history of abuse, especially physical abuse, had a poorer response to combination treatment with medication and psychotherapy [14]. These patients with a history of abuse may require specialized treatment. Adolescents with treatment-resistant depression had better treatment response if substance abuse-related impairment was low at baseline or reduced during treatment [15]. Suicidal adverse events during treatment of adolescent refractory depression were predicted by high suicidal ideations, family conflict and drug abuse at baseline. These predictors of suicidal adverse events also predict poor treatment response, and hence targeting suicidal ideations, family conflict and drug abuse can improve treatment outcomes [16]. Parent-child conflict has a bidirectional relationship with treatment outcome in adolescent treatment resistant depression [17]. Anhedonia in depressed adolescent’s refractory to medication treatment predicted longer time to remission and fewer depression-free days [18]. Depression severity and subsyndromal manic symptoms predicted poor treatment response in this sample [19]. There is also suggestion that adjunctive sleep medication to SSRI treatment in this sample may be associated with poor response [20]. Interestingly, if treatment ends during school summer break,
there was an improved treatment response [21]. Noncompliance with taking prescribed antidepressant treatment is common and associated with poor response [22]. No genetic polymorphisms were found to be associated with treatment response [23].

**Options for Treatment-Resistant Depression in Youth**

Current options for treatment-resistant depression in youth include optimizing the dose and duration of the current antidepressant, switching to another antidepressant within the same class, switching to another antidepressant in a different class, augmentation of the antidepressant, or combination [24]. More aggressive treatment includes Monoamine Oxidase Inhibitors (MAOI) or Electroconvulsive Therapy (ECT). Overall, minimal data exists to guide clinicians in treating refractory depression in youth.

**Optimizing the Dose and Duration of the Current Antidepressant**

Approximately one-third of adolescent patients with treatment-resistant depression will have achieved remission with continued treatment to 24 weeks. Those who responded by week 12 were also more likely to achieve remission [25]. In the same sample, subjects treated with citalopram and fluoxetine whose plasma concentration was equal to or greater than the geometric mean had a better treatment outcome than those whose plasma concentration was below the geometric mean. Plasma levels of paroxetine and venlafaxine was not associated with treatment outcome [26]. The data suggests optimizing the duration of antidepressant treatment, and dose optimization is suggested for paroxetine and venlafaxine. More studies are needed for optimal dosing and duration.

**Switching to another Antidepressant**

From data contained in a randomized controlled trial, adolescents with SSRI-resistant depression were switched to another SSRI or venlafaxine, while adding CBT, and 54.8% responded. The remission rate for a medication switch without concurrent CBT was lower at 40.5% [10]. Switching to amitryptyline or placebo in a controlled trial in a sample of adolescents with treatment resistant depression did not show any significant differences [27]. One case report provided information on MAOIs for treatment resistant depression in adolescents. Strober et al. [28] described two case reports of a 13 year old and 16 year old that was both refractory to previous antidepressant treatments, and both exhibited severe melancholic type illness characterized by psychomotor retardation) [6,8].

**Augmentation with Lithium**

There are two prospective studies of lithium augmentation in adolescents with depression unresponsive to tricyclic antidepressants [29,30]. In these two studies, less than half responded to lithium augmentation, and adverse side effects were noted. Lithium did show efficacy for adolescent bipolar disorder with comorbid substance dependence, compared to placebo [31]. However, a placebo-controlled study of lithium in depressed youth at high risk for bipolarity did not show separation from placebo [32]. From these preliminary studies, lithium may have a role in treatment-resistant depression in adolescents, especially those at risk for bipolar disorder (family history of bipolar disorder, acute onset of depressive episode, and marked psychomotor retardation) [6,8].

**Augmentation with Thyroid Hormone**

Surprisingly, no studies are available to inform us on the utility of thyroid hormone augmentation in adolescent treatment-resistant depression. For adults with treatment resistant depression, thyroid hormone is a viable option when used to augment an antidepressant [33]. Thyroid hormone also has a better side effect profile when compared to other augmenting agents like lithium. It is worth addressing the lack of data for thyroid hormone augmentation in adolescent treatment resistant depression, even in the form of a case series or open trial.

**Augmentation with Lamotrigine**

A couple of case series have shown promising results for lamotrigine in treatment depression in adolescents [34,35]. In the first case series, both adolescent patients with depression refractory to antidepressants responded and remitted with the addition of lamotrigine [34]. In the second study, 6 of 12 patients with treatment resistant depression responded to lamotrigine, and one patient with depression developed benign rash with lamotrigine [35]. Although the data on lamotrigine in adolescent refractory depression are non-controlled, retrospective studies, they provide valuable information regarding safety and tolerability.

The risk of serious rash (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis) associated with lamotrigine has limited its use in youth with mood disorders. Studies of lamotrigine in epilepsy indicate that the risk factors associated with serious rash and lamotrigine treatment include young age, high starting dose, rapid dose escalation, and addition of lamotrigine to valproate [36]. Starting at low doses and titrating slowly over 6 to 8 weeks may help to decrease the risk of rash. Most treatment-emergent rashes will most likely be benign and reversible.

Lamotrigine may have a role in augmenting an antidepressant for treatment resistant depression in adolescents, but randomized controlled trials are needed. Serious, life-threatening rash can be avoided by dosing low and titrating slowly over a period of several weeks. Detailed information for prescribing lamotrigine in adolescents with refractory mood disorders can be found elsewhere [37,35].

**Augmentation with Antipsychotics**

Two case studies provide data on augmentation with antipsychotics for adolescent treatment-resistant depression [38,39]. The first study examined 10 adolescents with major depressive disorder who did not respond to their antidepressant. When quetiapine was added to their antidepressant, 70% responded, with the most common sides effects being sedation and weight gain [38]. In the second case study,
2 adolescents with major depressive disorder were described, and both failed to respond to antidepressant treatment. The addition of quetiapine helped both patients remit, and quetiapine appeared to address the target symptoms refractory to SSRIs, which included sleep disturbance and self-harm [39]. Quetiapine may have a role as adjunctive treatment in adolescent treatment-resistant depression, being mindful of the metabolic effects of antipsychotics.

**Electroconvulsive Therapy (ECT)**

Some adolescents with depression fail to respond to multiple medication trials and psychotherapy, and continue to have unrelenting depressive symptoms impacting their functioning. This group of adolescents may be candidates for Electroconvulsive Therapy (ECT). Mood disorders have a response rate of 75-100% to ECT [40].

Multiple studies exist regarding ECT for adolescent treatment-resistant depression. In the only prospective study, 10 adolescents with treatment-resistant depression with psychosis were treated with ECT, with 9 responding. At 1 year follow-up, 9 were available, and 6 out of 9 were free of depressive symptoms [41].

The remaining studies are retrospective studies, most being case studies. In a case series of 6 adolescents with treatment-resistant depression, remission occurred in 5 out of 6 cases, and no cognitive impairments were noted [42]. There is also a case of successful right unilateral ultra-brief pulse electroconvulsive therapy in an adolescent with major depressive disorder with psychosis and catatonia [43]. A case report of a 13 year old female with treatment-resistant depression with psychosis responded to ECT [44]. A whole population study of ECT was conducted in adolescents, with 42 adolescents receiving ECT for major depression or psychotic depression. Mood disorders benefited most from ECT, while comorbid personality disorders predicted poor treatment outcome, and ECT only had minor adverse effects [45]. In another case series, three adolescents with major depression all responded to ECT, was well tolerated, and no relapse noted after one year follow-up [46]. Bloch et al. performed a chart review of 24 adolescent patients treated with ECT, 4 of which had depression, and 58% achieved remission [47,48] had another case series where response to ECT occurred in 5 out of 13 adolescents with major depressive disorder and 11 out of 13 adolescents with psychotic depression. In a review of all ECT studies published at the time of publication, 40 adolescents with depression had a 63% response rate [49]. ECT appears to be a viable option for treatment-resistant depression in adolescents, although controlled trials are lacking.

**Repetitive Transcranial Magnetic Stimulation (rTMS)**

Repetitive Transcranial Magnetic Stimulation is emerging as a treatment option for depression in adults, and has a few studies in adolescent depression [50] conducted an open-label trial of rTMS in 9 adolescents with treatment-resistant depression, and 3 responded, and only mild side effects. From the same sample, 8 of these study participants were followed for 3 years, and found that no cognitive deterioration occurred and some subjects maintained clinical improvement after treatment [51]. Wall et al. [52] followed 7 of 8 adolescents in an open trial of rTMS for 6 months, and found rTMS to be safe and was the preferred treatment over medication for the majority of patients and their parents. In a double-blind, sham-controlled trial of rTMS in 2 adolescents with depression (one medication refractory and the other medication naive), both subjects responded to active treatment [53]. In a case series, 2 out of 3 adolescents with treatment-resistant depression responded to ECT [54]. rTMS appears to be a promising treatment option for adolescent depression, given its relative lack of adverse effects. Although rTMS has FDA approval for adolescent treatment-resistant depression, well-designed, sham-controlled studies are needed.

**Psychosocial Treatments**

As mentioned earlier, adding CBT to an antidepressant led to better treatment outcomes than medication alone [10], and combination treatment is cost effective [55]. In addition, adding CBT to an antidepressant had even better response compared to medication alone when the adolescent with depression had other comorbid disorders [56]. Also mentioned earlier was that family conflict was associated with poor treatment response, so addressing family problems is important for successful outcomes [16]. In a sample of adolescents with treatment resistant depression, those who received more than 9 sessions of adjunctive CBT were 2.5 times more likely to have treatment response than those who received 9 or fewer sessions, and those who received social skills and problem solving components were also more likely to respond [57].

For adolescent treatment resistant depression, the data suggests adding a course of CBT to antidepressant treatment, especially for those patients who have other comorbidities. In addition, the data also suggests an adequate number of CBT sessions, especially focusing on social skills and problem solving. In addition, addressing family conflict is important for having good outcomes.

**Conclusion**

Before considering treatments for refractory depression, the clinician needs to determine if the diagnosis of Major Depressive Disorder is correct, or if other factors are present (i.e. history of physical/sexual abuse, suicidal ideations, family conflict, substance abuse, anhedonia, depression severity, subsyndromal manic symptoms, nonadherence to treatment) that are barriers to good treatment outcomes. For treatment-resistant depression, switching to another SSRI or to venlafaxine, and adding CBT has significant data supporting this option, as many patients may respond. If this is not successful, then lithium augmentation to an antidepressant can be considered. However, if lithium is not effective or adverse effects occur, then lamotrigine can be considered, either in augmentation to an antidepressant or as monotherapy. MAOIs may also be considered, but the risk of hypertensive crisis and strict adherence to a MAOI diet may preclude its use in adolescents. ECT has a role for treatment-resistant depression, and may be the most effective option, although this is usually a last resort option, given the stigma associated with its use in young people, and uninformed government policies in some regions where the law requires multiple psychiatrists to concur on recommending ECT. Repetitive TMS is an intriguing, emerging treatment option, and given the lack of adverse effects, it is worth exploring this treatment option further. Clearly, more controlled studies are needed with regards to switching strategies, combination strategies, augmentation strategies, ECT and TMS in adolescent treatment-resistant depression.

Finally, given the complexity and multitudes of variables which may exacerbate and perpetuate a depressive episode, the clinician needs to have a broad approach and utilize various modalities to shore up the patient's inner and outer resources to help alleviate the agony and demoralization associated with unrelenting depression. Medications may not be sufficient alone to address all the external pathologies that often occur with depression. This is the value of a psychiatrist and a multidisciplinary team, utilizing a broad biopsychosocial approach [58], to deal with complex, multifactorial, treatment-resistant medical
illness. Conducting a comprehensive pediatric psychopharmacology assessment incorporating both internal and external factors can be found elsewhere [59].

Disclosure

Dr. Carandang has no current financial ties.

References

1. Rao U, Weissman MM, Martin JA, Hammond RW (1993) Childhood depression and risk of suicide: a preliminary report of a longitudinal study. J Am Acad Child Adolesc Psychiatry 32: 21-27.

2. Kovacs M, Feinberg TL, Couse-Novak MA, Paulauskas SL, Finkelstein R (1984) Depressive disorders in childhood. I. A longitudinal prospective study of characteristics and recovery. Arch Gen Psychiatry 41: 229-237.

3. Kovacs M, Feinberg TL, Couse-Novak MA, Paulauskas SL, Pollock M, et al. (1984) Depressive disorders in childhood. II. A longitudinal study of the risk for a subsequent major depression. Arch Gen Psychiatry 41: 643-649.

4. Birmaher B, Brent DA, Kolko D, Baughner M, Bridge J, et al. (2000) Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 57: 29-36.

5. March J, Silva S, Petrycki S, Curry J, Wells K, et al. (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for depression Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. J Am Med Assoc 292: 807-820.

6. Strober M, Carlson G (1982) Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry 39: 549-555.

7. Strober M, Lampert C, Schmidt S, Morrell W (1993) The course of major depressive disorder in adolescents: I. Recovery and risk of manic switching in a follow-up of psychotic and nonpsychotic subtypes. J Am Acad Child Adolesc Psychiatry 32: 34-42.

8. Geller B, Fox LW, Clark KA (1994) Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 33: 461-468.

9. Puig-Antich J, Goetz D, Davies M, Kaplan T, Davies S, et al. (1989) A controlled family history study of prepubertal major depressive disorder. Arch Psychiatry 46: 406-418.

10. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, et al. (2008) Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 299: 901-913.

11. Vitelio B, Emslie G, Clarke G, Wagner K, Asarnow J.R, et al. (2011) Long-term outcome of adolescent depression initially resistant to SSRI treatment. Journal of Clinical Psychiatry 72:388-396.

12. Jureidini JD, Doeceke CJ, Mansfield PR, Haby MM, Menkes DB, et al. (2004) Efficacy and safety of antidepressants for children and adolescents BMJ 328: 879-883.

13. Carandang C.G, and Martin A (2009a) “Clinical Assessment of Children and Adolescents With Depression” in Treating Child and Adolescent Depression, (1st edn) Lippincott Williams & Wilkins, Baltimore, USA.

14. Shamseddeen W, Asarnow JR, Clarke G, Vitelio B, Wagner KD, et al. (2011a) Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescents Study (TORDIA). Journal of the American Academy of Child and Adolescent Psychiatry 50: 293-301.

15. Goldstein BI, Shamseddeen W, Spinto A, Emslie G, Clarke G, et al. (2009) Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry 48: 1182-1192.

16. Brent D.A, Emslie G.J, Clarke G.N, Asarnow J, Spinto A, et al. (2009) Predictors of spontaneous and systematicallyassessedsuicidalbehavior in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry 166:418-426.

17. Rengasamy M, Mansoor BM, Hilton R, Porta G, He J, et al. (2013) The bi-directional relationship between parent-child conflict and treatment outcome in treatment-resistant adolescent depression. Journal of the American Academy of Child and Adolescent Psychiatry 52:370-377.

18. McMakin D.L, Olino T.M, Porta G, Dietz L.J, Emslie G, et al. (2012) Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry 51: 404-411.

19. Maalouf FT, Porta G, Vitelio B, Emslie G, Mayes T, et al. (2012) Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. J Affect Disord 138: 86-95.

20. Shamseddeen W, Clarke G, Keller M.B, Wagner K.D, Birmaher B, et al. (2012) Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol 22: 29-36.

21. Shamseddeen W, Clarke G, Wagner K.D, Ryan ND, Birmaher B, et al. (2011b) Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break. J Am Acad Child Adolesc Psychiatry 50: 1140-1148.

22. Woldu H, Porta G, Goldstein T, Sakolsky D, Perel J, et al. (2011) Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry 50: 490-498.

23. Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, et al. (2010) Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 167. 190-197.

24. American Academy Child and Adolescent Psychiatry (1998) Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37:...: 635-638.

25. Emslie GJ, Mayes T, Porta G, Vitelio B, Clarke G, et al. (2010) Treatment of resistant depression in adolescents (TORDIA): week24 outcomes. Am J Psychiatry 167: 782-791.

26. Sakolsky DJ, Perel JM, Emslie GJ, Clarke GN, Wagner KD, et al. (2011) Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol 31: 92-97.

27. Birmaher B, Waterman GS, Ryan ND, Perel J, McNabb J, et al. (1998) Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. Journal of the American Academy of Child and Adolescent Psychiatry 37: 527-535.

28. Strober M, Patalo C, DeAntonio M (1998) Complete remission of ‘treatment resistant’ severe melancholia in adolescents with phenelzine: two case reports. J Affect Disord 50: 55-58.

29. Ryan ND, Meyer V, Dachille S, Mazzie D, Puig-Antich J (1988) Lithium antidepressant augmentation in TCA-refractory depression in adolescents. J Am Acad Child Adolesc Psychiatry 27: 371-375.

30. Strober M, Freeman R, Rigali J, Schmidt S, Diamond R (1992) The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. J Am Acad Child Adolesc Psychiatry 31: 16-20.

31. Geller B, Cooper TB, Sun K, Zimmerman B, Frazier J, et al. (1998) Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Psychiatry 37: 171-178.

32. Geller B, Cooper TB, Zimmerman B, Frazier J, Williams M, et al. (1998) Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study. J Affect Disord 51: 165-175.

33. Connolly KR, Thase ME (2011) If at first you don’t succeeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71: 43-64.

34. Carandang CG, Maxwell DJ, Robbins DR, Oesterheld JR (2003) Lamotrigine in adolescent mood disorders. J Am Acad Child Adolesc Psychiatry 42: 750-751.

35. Carandang CG, Robbins D, Mullany E, Yazbek M, Minot S (2007) Lamotrigine in adolescent mood disorders: a retrospective chart review. J Can Acad Child Adolesc Psychiatry 16: 1-8.

36. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowney MS, et al. (1999) Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40: 985-991.
37. Carandang CG (2006) Lamotrigine in Adolescent Treatment-Resistant Depression. Child and Adolescent Psychopharmacology News 11:1-10.

38. Pathak S, Johns ES, Kowatch RA (2005) Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacol 15: 696-702.

39. Good CR (2006) Adjunctive quetiapine targets self-harm behaviors in adolescent females with major depressive disorder. J Child Adolesc Psychopharmacol 16: 235-236.

40. Ghaziuddin N, Katcher SP, Knapp P; American Academy of Child and Adolescent Psychiatry Work Group on Quality Issues (2004) Summary of the practice parameter for the use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry 43: 119-122.

41. Strober M, Rao U, DeAntonio M, Liston E, State M, et al. (1998b) Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy. Biological Psychiatry, 43:335-338.

42. Ghaziuddin N, Dumas S, Hodges E (2011) Use of continuation or maintenance electroconvulsive therapy in adolescents with severe treatment-resistant depression. J ECT 27: 168-174.

43. Rhoads JC, Votolato NA, Young JL, Gilchrist RH (2010) The successful use of right unilateral ultra-brief pulse electroconvulsive therapy in an adolescent with catatonia. Brain Stimul 3: 51-53.

44. Segal J, Szabo CP, du Toit J (2004) Child and adolescent electroconvulsive therapy: a case report. World J Biol Psychiatry 5: 221-229.

45. Connor DF, Meltzer BM (2006) Pediatric Psychopharmacology: Fast Facts, New York: W.W. Norton & Company.

46. Etaib B, Le Heuzey MF, Mouren-Simeoni MC (2001) Electroconvulsive therapy in adolescents: clinical considerations apropos of a series of cases. Can J Psychiatry 46: 976-981.

47. Bloch Y, Levovitch Y, Bloch AM, Mendlovic S, Ratzoni G (2001) Electroconvulsive therapy in adolescents: similarities to and differences from adults. J Am Acad Child Adolesc Psychiatry 40: 1332-1336.

48. Walter G, Rey JM (1997) An epidemiological study of the use of ECT in adolescents. J Am Acad Child Adolesc Psychiatry 36: 809-815.

49. Rey JM, Walter G (1997) Half a century of ECT use in young people. Am J Psychiatry 154: 595-602.

50. Bloch Y, Grisaru N, Harel EV, Beilf G, Faivel N, et al. (2008) Repetitive transcranial magnetic stimulation in the treatment of depression in adolescents: an open-label study. J ECT 24: 156-159.

51. Mayer G, Aviram S, Walter G, Levkovitz Y, Bloch Y (2012) Long-term follow-up of adolescents with resistant depression treated with repetitive transcranial magnetic stimulation. J ECT 28: 84-86.

52. Wall CA, Cronkite PE, Sim LA, Husain MM, Janicak PG, et al. (2011) Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: a prospective, open pilot study. J Clin Psychiatry 72: 1263-1269.

53. Loo C, McFarquhar T, Walter G (2006) Transcranial magnetic stimulation in adolescent depression. Australas Psychiatry 14: 81-85.

54. Walter G, Tormos JM, Israel JA, Pascual-Leone A (2001) Transcranial magnetic stimulation in young persons: a review of known cases. J Child Adolesc Psychopharmacol 11: 69-75.

55. Lynch F.L, Dickerson J.F, Clarke G, Vitiello B, Porta G, et al. (2011) Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Archives of General Psychiatry 68:253-262.

56. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spira T, et al. (2009) Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 48: 330-339.

57. Kennard BD, Clarke GN, Weersing VR, Asarnow JR, Shamseddine W, et al. (2009) Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: preliminary findings. J Consult Clin Psychol 77: 1033-1041.

58. Carandang CG (2009) Response to Commentary: Biopsychosocial assessment: why the biopsyc and rarely the social? J Can Acad Child Adolesc Psychiatry 18: 348.

59. Carandang C, Kratochvil C, Scaghill L, Martin A. (2010) Chapter 27: Running a Pediatric Psychopharmacology Clinic: Practical Aspects, Pediatric Psychopharmacology: Principles and Practice (2nd edn) Oxford University Press, New York, USA.